{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:53:10Z","timestamp":1764510790620,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,5,25]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin's lymphoma with a variable clinical course. Central nervous system (CNS) involvement is a rare and dreaded complication in MCL. We report a case of leptomeningeal relapse of MCL that was successfully treated with a single-agent Bruton\u2019s tyrosine kinase inhibitor. A man in his 50s with MCL was treated with six cycles of bendamustine\u2013rituximab, achieving a complete remission (CR) and was subsequently placed on rituximab maintenance for 2 years. Four years later, he was hospitalised with symptoms of organic brain syndrome. Brain MRI and cerebrospinal fluid analysis confirmed CNS relapse of MCL. He was treated with dexamethasone, ibrutinib 560\u2009mg\/day and intrathecal cytarabine with improvement in neurological symptoms, and a follow-up MRI showed CR. The patient was later switched to acalabrutinib due to intolerance to ibrutinib. The patient is tolerating this regimen well, remaining in CR 3 years later.<\/jats:p>","DOI":"10.1136\/bcr-2022-249631","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T12:02:27Z","timestamp":1655899347000},"page":"e249631","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Durable remission with Bruton\u2019s tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-329X","authenticated-orcid":false,"given":"Binoy","family":"Yohannan","sequence":"first","affiliation":[{"name":"Hematology and Oncology, The University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-3322","authenticated-orcid":false,"given":"Arthi","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nghia","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adan","family":"Rios","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, The University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"2025082700082961000_15.6.e249631.1","doi-asserted-by":"crossref","unstructured":"Swerdlow SH , Campo E , Pileri SA . Swerdlow 2016. Blood 2016;127.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025082700082961000_15.6.e249631.2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.19"},{"key":"2025082700082961000_15.6.e249631.3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23615"},{"key":"2025082700082961000_15.6.e249631.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"2025082700082961000_15.6.e249631.5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e19527","article-title":"Outcomes in mantle cell lymphoma with central nervous system involvement","volume":"39","author":"McLaughlin","year":"2021","journal-title":"JCO"},{"key":"2025082700082961000_15.6.e249631.6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv074"},{"key":"2025082700082961000_15.6.e249631.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"2025082700082961000_15.6.e249631.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"2025082700082961000_15.6.e249631.9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"2025082700082961000_15.6.e249631.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647834"},{"key":"2025082700082961000_15.6.e249631.11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.14122","article-title":"Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom","volume":"178","author":"Tucker","year":"2017","journal-title":"Br J Haematol"},{"key":"2025082700082961000_15.6.e249631.12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.54_2630","article-title":"Ibrutinib compared to standard chemotherapy for central nervous system recurrence of mantle cell lymphoma","volume":"37","author":"Rusconi","year":"2019","journal-title":"Hematol Oncol"},{"key":"2025082700082961000_15.6.e249631.13","first-page":"1","article-title":"Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review","volume":"2017","author":"Mannina","year":"2017","journal-title":"Case Rep Hematol"},{"key":"2025082700082961000_15.6.e249631.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"2025082700082961000_15.6.e249631.15","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"2025082700082961000_15.6.e249631.16","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Advances"},{"key":"2025082700082961000_15.6.e249631.17","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/HS9.0000000000000155","article-title":"Efficacy of Zanubrutinib in the treatment of Bing-Neel syndrome","volume":"2","author":"Wong","year":"2018","journal-title":"Hemasphere"},{"key":"2025082700082961000_15.6.e249631.18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(21)00235-X","article-title":"Pirtobrutinib shows evidence to inaugurate a third generation of Btk inhibitors","volume":"397","author":"Michot","year":"2021","journal-title":"Lancet"},{"key":"2025082700082961000_15.6.e249631.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"},{"key":"2025082700082961000_15.6.e249631.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025082700082961000_15.6.e249631.21","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"Car T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"key":"2025082700082961000_15.6.e249631.22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13149"},{"key":"2025082700082961000_15.6.e249631.23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25796"},{"key":"2025082700082961000_15.6.e249631.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"2025082700082961000_15.6.e249631.25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-249631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:08:40Z","timestamp":1756278520000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-249631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,22]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bcr-2022-249631"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-249631","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}